3B BlackBio Dx Ltd (3BBLACKBIO) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company reported a consolidated growth of 11.8% year-over-year; however, when adjusted for the seasonal spike in dengue and flu cases from the previous year, the underlying growth is over 20%.
- Exports are performing strongly, with a growth forecast of 15-20%, driven by the UK subsidiary which is now exporting to 70 countries and benefiting from the "Made in UK" branding.
- The company maintains a significant market share of 12-15% in the addressable Indian molecular diagnostics reagent market, which is estimated to be around INR 400-500 crores.
- Strategic initiatives are progressing, including the development of a sample-to-answer machine and a Point-of-Care (POC) system to target new market segments within infectious diseases and oncology.
- The recent acquisition of Chorus (Belgium) is being integrated as a standalone business, with a focus on its lateral flow and AMR products, and has initiated the USFDA registration process to enter the US market.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.